Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
New vaccines study findings have been reported from J.T. Lin et al
February 18th, 2009
According to recent research from Beijing, People's Republic of China, "An inactivated, alum-adjuvanted, whole-virion H5N1 vaccine had been evaluated previously. Hemagglutination inhibition ( HI) assays showed that the antibody levels declined significantly, with 4.8%-20.8% and 0%-18.8% of participants retaining seroprotection (HI titer >= 1:40) 6 and 12 months after the second dose, respectively." "A third dose of the same vaccine given 12 months after the second dose significantly boosted immune responses. Thirty days after the third dose in the 1.25-, 2.5-, 5-, and 10-mu g dose groups, 29.4%, 31.3%, 78.6%, and 90.0% of participants had HI titers >= 1:40,...
Source: Vaccine Weekly (2009-02-18)
|
